Tags
AGI Therapeutics, Ark Therapeutics, Carl Icahn, catalyst, Daniel Loeb, Recommended Cash Offer, Risk Arbitrage, Seth Klarman, TGISVP
This post, and this one here, are good required reading. Yes, AGI Therapeutics (AGI:ID/LN) was the Risk Arb investment to which I was referring.
This is the one Irish share I did not disclose owning during TGISVP. My apologies, readers – but AGI trading volumes were atrocious, and I was still building a position with great difficulty. However, when I got to covering AGI during TGISVP, I simply tagged its fair value as simply being equal to the Recommended Cash Offer – so no issues there, I believe. Now that I recently received my final batch of proceeds from the AGI takeover, I thought it might be useful/interesting to walk through my thinking and exact positioning throughout the process.